Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
Follow AMGN
Amgen Inc. (AMGN) Net income
Amgen Inc.'s net income for fiscal 2025 was $7.7B, up 88.5% from $4.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $8.7B. Over the past ten years it has ranged from $2.0B (fiscal 2017) to $8.4B (fiscal 2018); the current reading is higher than 73% of that period. Amgen Inc. ranks 7th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $7.7B | 88.53% |
| FY2024 | $4.1B | (39.11%) |
| FY2023 | $6.7B | 2.52% |
| FY2022 | $6.6B | 11.18% |
| FY2021 | $5.9B | (18.87%) |
| FY2020 | $7.3B | (7.37%) |
| FY2019 | $7.8B | (6.58%) |
| FY2018 | $8.4B | 324.15% |
| FY2017 | $2.0B | (74.37%) |
| FY2016 | $7.7B | 11.28% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $2.4B | 30.57% |
| Mar 2026 | $1.8B | 36.46% |
| Dec 2025 | $1.3B | (58.55%) |
| Sep 2025 | $3.2B | 124.58% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| AMGN Amgen Inc. | $8.7B |
| ABBV AbbVie Inc. compare | $6.3B |
| PFE Pfizer Inc. compare | $4.4B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on AMGN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement